Pharmaceutical company Vivera Pharmaceuticals Inc Wednesday expanded access to testing resources, vaccine clinics and personal protective equipment (PPE) following the new mask and testing mandates across the nation due to increase in COVID-19 cases in the US.
The company has announced a resurgence of hospitalizations due to more transmissible mutations of the Delta variant. The State of California, New York City and the Department of Veteran Affairs have been among the first to announce plans to regularly test unvaccinated employees and advise masks for employees and workers in health care and high-risk congregate settings.
In the State of California, the company offers complimentary, concierge COVID-19 testing solutions for businesses, government establishments, educational institutions, event sites, long-term care facilities as well as other group settings.
According to the company, it continues to support first responders, health care workers and federally qualified health care centres to meet the demand for affordable PPE with an adequate supply of gloves and masks manufactured in the USA as most of the schools reopen. It hopes to help the country get ahead of the curve to slow the spread of COVID-19 to keep communities safe.
Circio unveils circVec proof-of-concept
GSK releases decade-long data on Shingrix efficacy
BiVictriX receives FDA Orphan Drug Designation for AML treatment candidate
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
GSK's meningitis vaccine candidate accepted for FDA review
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
ProAxsis secures GBP1.8m investment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients